Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TD-1473 RHEA phase 2b/3 induction and maintenance study in ulcerative colitis
MOH_2019-05-08_004941Phase 3Not yet recruiting
- Sponsor
- Theravance Biopharma, Inc.
- Start
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of izencitinib in autoimmune colitis (4 arms), sponsored by Theravance Biopharma, Inc. Planned start Jan 2019; status: not yet recruiting.
02
Drugs
izencitinib
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on MOH_2019-05-08_004941.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-05-08_004941.